Sign in

    Lily Young

    Research Analyst at Leerink Partners

    Lily Young is an Equity Research Analyst at Leerink Partners, focusing on coverage within the healthcare and biotechnology sectors. She covers major public companies in pharma and biotech, leveraging deep sector knowledge to provide actionable insights for institutional clients, though detailed performance metrics or public rankings like TipRanks are not available. Lily began her career in investment research shortly after graduating and has advanced at Leerink Partners, with no public record indicating prior positions at other firms. She holds Series 7 and 63 securities licenses and is registered with FINRA as required for her analyst role.

    Lily Young's questions to IONIS PHARMACEUTICALS (IONS) leadership

    Lily Young's questions to IONIS PHARMACEUTICALS (IONS) leadership • Q1 2025

    Question

    Lily Young, on for Mani Foroohar, asked for more detail on the distribution of TRYNGOLZA patients between newly and previously diagnosed, and how that mix is expected to evolve.

    Answer

    Chief Global Product Strategy Officer Kyle Jenne stated that while specific patient numbers would not be disclosed, the company is encouraged by new patient identification and expects incremental additions quarterly. CEO Brett Monia clarified that going forward, growth depends on identifying new patients, as the initial bolus of known and clinical trial patients has been largely addressed. Chief Commercial Officer Jonathan Birchall added that growing awareness is motivating physicians to diagnose more actively.

    Ask Fintool Equity Research AI